In two phase 3 clinical trials, retatrutide, a novel glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and glucagon triple-hormone receptor agonist, demonstrated significant weight loss and clinically meaningful improvements in health outcomes in people living with obesity and type 2 diabetes
Frequently Asked Questions (FAQs) What is the GHK-Cu peptide used for
That's an availability and continuity question, and it's legitimately urgent in a way that a year ago it wasn't
metabolite Ac-LKKTE identified as potentially more active than parent compound Paradoxical finding: Both peptides show biological effects persisting hours to days after administration despite rapid plasma clearance Possible explanations: Tissue retention, active metabolites, or persistent signaling cascade activation Excretion Pathways Limited data exists on excretion for both peptides[22]: Likely renal elimination of peptide fragments Hepatic metabolism may contribute to clearance No accumulation detected in chronic dosing studies (animal models) Combined excretion kinetics have not been characterized in any species The disconnect between short plasma half-lives and prolonged biological effects represents a key area requiring mechanistic clarification for both individual peptides and their combination
Nonetheless, the posts are very short for novices